D004

I hereby certify that this correspondence is being sent by facsimile transmission in accordance with § 1.6(d) addressed to Art Unit 1652, After Final Facsimile No. (703) 872-9307, Box CPA, Commissioner for Patents, Washington, D.C. 20231 on the date shown below. September 16, 2002 PATENT TRADEMARK OFFICE PATENT Docket No. GC396-2 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE CONTINUED PROSECUTION APPLICATION (CPA) REQUEST TRANSMITTAL Commissioner for Patents Box CPA Washington, D.C. 20231 Şir: This is a request for filing a
continuation divisional application under 37 CFR 1.53(d), (continued prosecution application (CPA)) of prior application number 09/262,126 filed on March 3, 1999, entitled Modified Forms of Pullulanase. under 37 CFR ☐ Enter the unentered amendment previously filed on ____ 1.116 in the prior non-provisional application. A preliminary amendment is enclosed. This application is filed by fewer than all inventors named in the prior application, 37 CFR 3. 1.53(d)(4). a. DELETE the following inventor(s) named in the prior non-provisional application: b. The inventor(s) to be deleted are set forth on a separate sheet attached hereto. ☐ A new power of attorney or authorization of agent (PTO/SB/81) is enclosed. Information Disclosure Statement (IDS) is enclosed: a. PTO-1449 Copies of IDS Citations

GC396-2 CPAtran

Docket No. GC396-2 Page 2

CLAIMS					
	NO. OF CLAIMS		EXTRA CLAIMS	RATE	FEE
Basic Application Fee (37 CFR 1.16(a))					\$740.00
Total Claims (37 CFR 1.16(c))	29	-20 =	9	9 x \$18.00 =	\$162.00
Independent Claims (37 CFR 1.18(b))	8	-3 =	5	5 x \$84.00 =	420.00
Multiple Dependent Claims (if applicable) + \$280.00 =					
TOTAL APPLICATION FEE DUE					\$1,322.00

6 🖂	Applicant requests suspension of action under 37 CFR 1.103(b) for a period of three
	(not to exceed 3 months) and the fee under 37 CFR 1.17(i) is enclosed.
monuns	(Inditio exceed 5 inditions) and the reconnection of the first type of the contract of the con

7. Other:

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 07-1048 (Docket No. GC396-2). A duplicate of this paper is enclosed.

Date:

9/13/02

Genencor International, Inc. 925 Page Mill Road Palo Alto, CA 94304-1013

Tel: 650-846-4020 Fax: 650-845-6504 Respectfully submitted

Registration No. 32,242

398-2 CPAtran

I hereby certify that this correspondence is being sent by facsimile transmission in accordance with § 1.6(d) addressed to Art Unit 1652, After Final Facsimile No. (703) 872-9307, Box CPA, Commissioner for Patents, Washington, D.C. 20231 on the date shown below.

September 16, 2002

PATENT Docket No. GC396-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application: Miller et al.

Serial No.: CPA of 09/262,126

Filed: March 3, 1999

For: Modified Forms of Pullulanase

Group Art Unit: 1652

Examiner: M. N. Rao, Ph.D.

PRELIMINARY AMENDMENT

BOX CPA Commissioner for Patents Washington, D.C. 20231

Sir:

The present application is being filed as a Continued Prosecution Application (CPA) of application serial number 09/262,126. Prior to examining the instant application on the merits, please enter the present amendment.

IN THE CLAIMS:

lease cancel claim 11.

Please enter the following clean copy of the amended claims. A marked-up version is attached hereto as Appendix I.

5. (Thrice amended) The pullulanase of Claim 6, wherein the pullulanase is obtained from a B. deramificans having the designation T89.117D in the LMG culture collection.

396-2(CPA)pAM